Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities
Initiatives to accelerate commercial effectiveness position the Company for growth in rest of 2026 and going
Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to discuss its third quarter 2026
NMPA approvals for Quanterix SIMOA® instruments and key neurology biomarker assays advance access to ultra-sensitive blood-based testing in China
Quanterix Corporation (NASDAQ:QTRX), a global leader in precision
Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development
Quanterix Corporation (NASDAQ:QTRX) today
Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the "Inducement Grants") were made to James Gute, the recently
Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this
Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences
Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities
Company accelerating initiatives to drive commercial effectiveness
Revises financial outlook for 2026 and extends date for
Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the
Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026
Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the "Inducement
Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD®
Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026,
Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business
Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics,
